الأحد 13 محرم 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| A Phase Ib study to determine the safety and immunogenicity of the candidate Middle East Res-piratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in healthy adult Middle Eastern volunteers | KAIMRC | Ongoing | vaccine ChAdOx1 MERS | 1 | CT18/004/R | King Abdulaziz Medical City NG (Riyadh) |
| Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia | Hikma | Rejected | Dasatinib | 2 | LPI-JOR-LEB-KSA-TUN- | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease. | Celgene | Ongoing | Ozanimod HCl | 3 | RPC01-3201 | King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease | Celgene | Ongoing | Ozanimod HCl | 3 | RPC01-3204 | King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| A multi-center open-label parallel group randomized controlled trial to compareiGlarLixi versus premixed insulin in patients with type 2 diabetes who have failedto achieve glycemic control with basal insulin and oral antidiabetic agents | Sanofi | Ongoing | Insulin glargine/Lixisenatide | 3b | LPS15017 | King Fahad Medical City (Riyadh) |
| A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease | Janssen-Cilag International NV | Ongoing | Guselkumab | 2 | CNTO1959CRD3001 | King Abdullah Medical City (Makkah), King Abdulaziz Medical City NG (Riyadh) |
| A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3) | Astrazeneca | Ongoing | Ticagrelor | 3 | D5136C00009 | King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh) |
| Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients: Prospective Randomized Control trial | King Fahad Hospital of the University | Completed | Ketamine | 3 | 2016-01-042 -Version 02 | King Fahad Hospital of the University |
| A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06687234 AS ADD-ON THERAPY TO INFLIXIMAB IN ACTIVE ULCERATIVE COLITIS SUBJECTS WHO ARE NOT IN REMISSION (BUILD UC) | Pfizer | Ongoing | PF-06687234 | 2 | B7581002 | King Abdulaziz Medical City NG (Riyadh), King Abdulaziz University Hospital (Jeddah), King Khalid University Hospital (Riyadh) |
| An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure | AstraZeneca | Ongoing | Dapagliflozin | 3 | D169CC00001 | King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz University Hospital (Jeddah), Saud Al-Babtain Cardiac Center (Dammam), King Abdulaziz Medical City NG (Riyadh), King Fahad Medical City (Riyadh) |
تاريخ آخر تحديث: 08/05/2025 بتمام الساعة 03:17 مساء بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.